PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation-Reference-Cited by-同舟云学术

PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation

Published:2021-02-10 Issue:4 Volume:20 Page:676-690
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Scarpa Mario,Singh Prerna,Bailey Christopher M.,Lee Jonelle K.,Kapoor Shivani,Lapidus Rena G.,Niyongere Sandrine,Sangodkar Jaya,Wang Yin,Perrotti Danilo,Narla Goutham,Baer Maria R.

Funder

Merit Review Award

Department of Veterans Affairs Biomedical Laboratory Research and Development Service

NIHNCINCI

NHLBI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis;Cell Communication and Signaling;2024-08-07

2. PIM kinase inhibitors: an updated patent review (2016-present);Expert Opinion on Therapeutic Patents;2024-05-03

3. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation;Cancer Research Communications;2024-02-16

4. Revving the engine: PKB/AKT as a key regulator of cellular glucose metabolism;Frontiers in Physiology;2024-01-08

5. Valtrate exerts anticancer effects on gastric cancer AGS cells by regulating reactive oxygen species-mediated signaling pathways;BIOCELL;2024